MRNAModerna
Moderna is a pioneer and leader in the field of mRNA medicine. 10-K, Item 1
- Employees
- 4,700
- Headquarters
- Cambridge, MA
- CEO
- Stephane Bancel
- Next results
- around Jan 11, 2027
The biggest changes in the 10-K filed 2026-02-20, this fiscal year against the last, and the sentences in the MD&A (Item 7) where management explains them, quoted word for word. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Operating margin
-121.9% → -158.1% (-36.2 pts) Big change FY to 2025-12-31 vs 2024-12-31The MD&A has no sentence that names a cause for this change. That can be worth a question: ask about the filing.
Revenue
-39.9% Big change FY to 2025-12-31 vs 2024-12-31“Total revenue decreased by $1.3 billion, or 40%, in 2025, primarily driven by a decline in net product sales.”
Read it in the 10-K ↗
“Net product sales decreased by $1.3 billion, or 42%, in 2025, largely due to lower sales volumes of our COVID vaccine across all regions.”
Read it in the 10-K ↗
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K ↗
Work on MRNA in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/MRNA/export.csv") into a cell.